Michael Dore
LOWENSTEIN SANDLER LLP
65 Livingston Avenue
Roseland, New Jersey 07068
(973) 597-2500
NJ License No. 034581980
Attorney for Defendants Warner Chilcott (US), LLC, as
Successor in interest to Procter & Gamble Pharmaceuticals
Inc., sanofi-aventis U.S. L.L.C., and Sanofi US Services Inc.

SEP 3 0 2015
JUDGE JESSICA R. MAYER

## IN THE SUPERIOR COURT OF NEW JERSEY LAW DIVISION, MIDDLESEX COUNTY

BELINDA MANNING,	x	
	:	
	:	
Plaintiff,	:	
***	:	
VS.	:	Civil Action No.: MID-L-6755-14
	:	Fosamax Litigation (Case No. 282)
MERCK SHARP & DOHME, CORP.; SANOFI US SERVICES INC.; SANOFI- AVENTIS LLC; WARNER CHILCOTT (US), LLC; AND PROCTER & GAMBLE PHARMACEUTICALS, INC.		STIPULATION AND ORDER OF DISMISSAL WITH PREJUDICE
Defendants.	: x	

IT IS HEREBY STIPULATED AND AGREED by and between Plaintiff Belinda Manning ("Plaintiff") and Defendant Warner Chilcott (US), LLC ("Warner Chilcott"), through their respective undersigned counsel, that all of Plaintiff's claims against sanofi US Services,

Inc., sanofi-aventis LLC, sanofi-aventis U.S., Inc., sanofi-aventis U.S. L.L.C.<sup>1</sup> Warner Chilcott (US) LLC, and Procter & Gamble Pharmaceuticals, Inc.<sup>2</sup> are hereby dismissed with prejudice pursuant to <u>Rule</u> 4:37-1(a) of the New Jersey Rules of Court. Each party will bear its own costs and fees.

Plaintiff's claims against Defendant Merck, Sharp & Dohme, Corp. are not dismissed by this Stipulation of Dismissal and remain pending.

DATED:

By: NWW/OG/O

The Levensten Law Firm, P.C.

1420 Walnut Street

Michael W. Johnston

**Suite 1500** 

Philadelphia, PA 19102

(215) 545-5600

Attorneys for Plaintiff

By:

Michael Dore

Lowenstein Sandler LLP 65 Livingston Avenue Roseland, NJ 07068

(973) 597-2500

Lana K. Varney

Norton Rose Fulbright US LLP

98 San Jacinto Blvd.

Suite 1100

Austin, TX 78701

(512) 474-5201

Attorneys for Defendants Warner Chilcott (US), LLC, sanofiaventis U.S. L.L.C., and Sanofi US Services Inc.

sanofi US Services, Inc. and sanofi-aventis LLC are improperly named. The proper sanofi entity is sanofi-aventis U.S. L.L.C. sanofi-aventis U.S. L.L.C. is the successor in interest to Aventis Pharmaceuticals, Inc. sanofi-aventis U.S. L.L.C. co-promoted Actonel® with Procter & Gamble Pharmaceuticals, Inc. until October 30, 2009, after which it co-promoted Actonel® with Warner Chilcott Pharmaceuticals Inc. until April 1, 2010. On April 1, 2010, sanofi-aventis U.S. L.L.C. ceased its co-promotion of Actonel®, and Warner-Chilcott Pharmaceuticals Inc. assumed full responsibility for the promotion of Actonel®.

<sup>&</sup>lt;sup>2</sup> On February 1, 2010, Procter & Gamble Pharmaceuticals, Inc. became known as Warner Chilcott Pharmaceuticals Inc. In connection with that name change, Warner Chilcott Pharmaceuticals Inc. served as the successor in interest to Procter & Gamble Pharmaceuticals, Inc. Effective as of January 1, 2011, Warner Chilcott Pharmaceuticals Inc. was merged into Warner Chilcott (US), LLC, and no longer exists as a distinct entity. In connection with this transaction, Warner Chilcott (US), LLC now serves as the successor in interest to Procter & Gamble Pharmaceuticals, Inc.

By: Lileen Oakes Muskett

Eov Rothschild LLP

Fox Rothschild LLP Midtown Building 1301 Atlantic Avenue Suite 400 Atlantic City, NJ 08401

Attorneys for Defendant Merck Sharp & Dohme, Corp.

SO ORDERED:

Honorable Jessica R. Mayer, J.S.C.

DATED:

\_, 2015